1. Introduction {#sec1}
===============

Narcotics are the mainstay analgesics to control pain in the intensive care settings. However, patients frequently require escalating doses of narcotics for pain control leading to higher risks of side effects and complications \[[@B1]\]. Previously, literature has mentioned various adjunctive therapies including N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan \[[@B2]\]. NMDA receptors are implicated in mediating a decrease in narcotic effect and hence, being an NMDA antagonist, dextromethorphan may supplement the pain control by narcotics but this has never been studied in a randomized controlled trial in children admitted in PICU and is still unclear \[[@B3], [@B4]\], although there had been reported results in adult population \[[@B5]--[@B8]\]. The aim of this prospective double-blind randomized controlled trial is to evaluate the role of dextromethorphan as an adjunct to narcotic analgesia in pediatric intensive care unit (PICU).

2. Methods {#sec2}
==========

2.1. Conduct of Study {#sec2.1}
---------------------

This interventional double-blind randomized clinical trial (RCT) was conducted between January 2011 and January 2015 at King Abdulaziz Medical City (KAMC), Riyadh, KSA, a 1500-bed medical university hospital. The PICU is a multidisciplinary unit admitting about 900 patients per year under 14 years of age. It was conducted observing the principles of Helsinki declaration. This study was approved by the Institutional Review Board and King Abdullah International Medical and Research Center (KAIMRC) and involved pediatric intensive care unit patients (2--14 years). This study is registered with clinicaltrials.gov (identifier: [NCT01553435](https://clinicaltrials.gov/ct2/show/NCT01553435?term=NCT01553435&rank=1)) and was approved by Saudi Food and Drug Administration to study off-label use of study medicine. The project was periodically audited and monitored by Clinical Trials Monitoring Unit of KAIMRC to ensure maintenance of standards according to Helsinki declaration and to ensure adherence to the approved protocol.

2.2. Primary Outcome and Definitions {#sec2.2}
------------------------------------

The primary outcome in this study was the cumulative dose of fentanyl in subjects with intervention of either dextromethorphan or placebo.

*Hemodynamic instability* was defined as a clinical state requiring pharmacologic support to maintain mean blood pressure between 10th and 90th percentile according to age and and/or to maintain capillary refill at less than 2 seconds.

*Liver failure or dysfunction* was defined as an increase in serum levels of aspartate transaminase (AST) or alanine transaminase (ALT) by at least twice the normal reference results for age.

*Multiple organ failure* was defined as the presence of deranged organ function involving two or more organ systems.

*Total infusion dose* was defined as the amount of fentanyl received during 96 hours per kilogram of body weight.

*Total cumulative dose of fentanyl* was defined as total infusion dose plus total intermittent (prn) doses of fentanyl per kilogram of body weight during 96 hours.

*Adequate pain control* was defined as FLACC score of zero (comfortable and relaxed) and/or faces score of zero (no pain).*Tolerance* was defined as the state of adaptation in which fentanyl exposure led to diminution of analgesic effects over time \[[@B9]\].

2.3. Study Protocol, Randomization, and Concealment {#sec2.3}
---------------------------------------------------

Upon admission all the patients were assessed for eligibility to be enrolled in the study as per inclusion and exclusion criteria. Inclusion criteria were as follows: (1) patients admitted in PICU within 72 hours of admission and (2) patients receiving intravenous infusion of fentanyl. The exclusion criteria were as follows: (1) patients who are less than 2 years of age, (2) patients who are hemodynamically instable, (3) enteral route which was contraindicated for medication administration, and (4) patients with hepatic or renal failure/dysfunction or multiorgan failure. Verbal and written information was provided to eligible patients/parent(s)/guardian(s). Informed consent was obtained once they decided to participate. Subjects\' biodata and consent were entered in hospital electronic order system for randomization. Sample size was calculated on the basis of an absolute enhanced effect of 75--100% and assuming 10% drop out rate our estimated sample size was total number of 36 to give study a power of 80%. 36 randomization numbers were allocated to two groups by random chance and each group received 18.

Subjects, parent(s)/guardian(s)/caregiver, investigators, pharmacists, nurses, and paramedics were kept blinded. The intervention in this study was administration of dextromethorphan via nasogastric or orogastric tube. The unblinded research pharmacist from KAIMRC prepared placebo medicine that was identical to dextromethorphan in physical properties.

2.4. Postenrollment Management {#sec2.4}
------------------------------

Intervention study medicine was administered every 8 hours through nasogastric or orogastric tube in the standard recommended doses of 0.3 mg per kilogram per dose by bedside nurse.

The total duration of intervention was 96 hours. During this time frame, we had criteria to remove subjects from study if one or more of the following circumstances arise: (a) if the narcotic infusion was discontinued, (b) if subject developed hemodynamic instability, (c) withdrawal request by parent(s)/guardian(s), and (d) if subject\'s Glasgow Coma Scale (GCS) fell below 5 or subject was declared dead.

Enrolled subjects were continuously monitored with PICU monitoring system and pain was assessed via FLACC (face, legs, activity, cry, and consolability) and/or faces scales by the staff who were well trained and experienced with the universally standard goal of achieving pain control with minimum dose of fentanyl \[[@B10]--[@B12]\]. Clinicians titrated the fentanyl infusion dose and administered intermittent bolus (prn) doses to maintain adequate pain control. Each subject\'s medical record was evaluated to record variables including age, weight, height, body mass index (BMI), gender, length of stay in PICU and hospital, PRISM score, admitting diagnosis, provision of antibiotics during study period, starting and end dose of narcotics, and biochemical profile. All the subjects received midazolam infusion as sedative. Moreover, subjects did not receive any other analgesic including acetaminophen, ketamine, and ketorolac, sedative, or paralytic agent.

2.5. Literature Search and Analysis {#sec2.5}
-----------------------------------

We searched literature in PubMed with mesh headings of analgesia, acute care, narcotics, fentanyl, morphine, adjunctive therapies, NMDA antagonists, and dextromethorphan.

We recorded the data on Microsoft Excel, version 2007. The data were then exported to IBM Statistical Package for Social Sciences Statistics, version 20 (IBM Inc., Armonk, New York, USA), for further analysis by intention to treat. Demographic variables were assessed using Kolmogorov-Smirnov test for distribution and reported as median with interquartile ranges (IQR) and groups were compared using Mann--Whitney test. Biochemical data and fentanyl doses group comparison are presented as means with standard deviation (SD) and groups were compared using Student\'s*t*-test. All the statistical tests were two-tailed. The significant level for results was set at *p* \< 0.05. In subgroup analysis we utilized Bonferroni correction to extract *p* value.

3. Results {#sec3}
==========

[Figure 1](#fig1){ref-type="fig"} outlines the flow diagram. We assessed all the PICU admissions in our 20-bed multidisciplinary PICU from 2011 to 2015 for enrollment. 2412 patients were assessed for eligibility according to inclusion and exclusion criteria. Among these, 2376 patients did not meet the inclusion criteria. Additional 27 patients were not included in the study because parents/guardians declined to participate in the study. 36 subjects were enrolled via double-blinded randomization and at the end 18 were randomized to each of the two groups. Later on two patients were excluded from group 1. The reason in the first case was that the subject\'s fentanyl infusion was discontinued by clinicians and in the second case the parents requested withdrawal from study for unspecified reasons. Five subjects were removed before completion of intervention from group 2 with the following reasons: (1) subject was declared brain dead, (2) fentanyl infusion was discontinued, (3) subject evolved multiple organ failure, (4) parents requested withdrawal from study due to uncertainty about pain control, and (5) fentanyl infusion was discontinued. Hence, 16 patients in group 1 and 13 patients in group 2 were included in the analysis.

In Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}, we present the characteristics of the subjects in group 1 (dextromethorphan) and group 2 (placebo). The mean age in group 1 is higher than that in placebo group (9.7 versus 5.54; *p*, 0.0015; CI 1.74--6.56). There is statistically no significant difference regarding length of stay in PICU or hospital, PRISM score, use of antibiotics, and mean fentanyl infusions at the beginning and end of study enrollment. Group 1 received three patients with hematology/oncology problems, while group 2 did not. On the contrary, group 2 had one burn patient while group 1 did not have any burn patient. Otherwise, there was no significant difference between the two groups regarding the number of patients who had diagnoses of trauma, postoperative care, and respiratory failure. We recorded fentanyl dose at the beginning and at the end for all the subjects during study period of 96 hours and the analysis did not reveal any significant difference between the two groups. Regarding biochemical profile, there is no statistical difference between the two groups.

In [Table 3](#tab3){ref-type="table"} the data presented are related to the comparison of fentanyl requirement in the two groups. We found no statistically significant difference in cumulative dose of fentanyl when administered with dextromethorphan (group 1) as compared to when administered with placebo (means, 217.9 versus 268; *p*, 0.127). Likewise, there is no statistical difference between the two groups regarding fentanyl whether administered as infusion or as prn bolus doses. This study found that when dextromethorphan was added, the accumulative requirements of fentanyl were less in subjects who were overweight (BMI more than 85%) as compared to the rest ([Figure 2](#fig2){ref-type="fig"}, *p* = 0.042).

4. Discussion {#sec4}
=============

Multiple therapies had been mentioned in the literature which are considered adjunctive to narcotics. Some of these are beneficial to patients who have chronic pain such as antidepressants and anticonvulsant and some are beneficial to patients with acute pain such as acetaminophen and ibuprofen \[[@B13]--[@B20]\]. Regarding the role of dextromethorphan as adjunctive therapy in acute intensive care settings, our prospective double-blinded randomized interventional trial did not detect any significant effect of adding dextromethorphan on the required total accumulative dose of fentanyl for 96 hours of enrollment (means, 217.9 versus 268; *p*, 0.127).

Dextromethorphan (DM) is an antitussive drug. It is one of the active ingredients used to prevent coughs in many over-the-counter cold and cough medicines. DM is the D-isomer of the codeine analog of levorphanol but has little analgesic or addictive properties. However, it does act on the cough center in the medulla oblongata by elevating the threshold for coughing. In usual doses, the drug can cause dilation of pupils, but without significant reduction of respiratory rate. Dextromethorphan may cause slight elevations in blood pressure \[[@B21]\]. DM has also found other uses in medicine, ranging from pain relief to psychological applications. DM as a noncompetitive NMDA receptor antagonist can be used to block NMDA receptors in a dose-dependent manner, thus reducing the receptor binding sites available to opioids and to some extent producing an attenuation of opioid tolerance.

Dextromethorphan (DM) may play an important role in conditions of glutamate excitotoxicity (i.e., amyotrophic lateral sclerosis) because of its ability to suppress the overactivity of the glutamate system in the CNS \[[@B22]\]. In vitro studies have shown that both DM and its major metabolite (dextrorphan) noncompetitively antagonize N-methyl-D-aspartate (NMDA) and glutamate-induced excitation and excitotoxicity in the CNS and spinal regions. In addition, DM has been shown to inhibit NMDA-induced convulsions and attenuate hypoglycemic neuronal injury \[[@B23], [@B24]\].

The researchers have explored the role of dextromethorphan as adjunct to narcotics pain control in acute setting. Elliott et al. performed an animal study and showed that dextromethorphan decreased the tolerance to analgesic effect of morphine \[[@B3]\]. They showed that the requirement was much less on day 4 of morphine therapy when dextromethorphan was coadministered in comparison to placebo. Likewise, Price et al. studied oral doses of dextromethorphan (DM) in normal volunteer human subjects who rated intensities of first and second pain in response to repeated painful stimuli \[[@B25]\]. They demonstrated beneficial effect of dextromethorphan. Similarly, Mao et al. studied combined administration of dextromethorphan and morphine in rats and showed beneficial effect \[[@B4]\]. They concluded that combining DM with opiate analgesics may be a powerful approach for simultaneously preventing opiate tolerance and dependence and enhancing analgesia in humans. However, our study results are in contradiction to these previous studies. We strongly recommend a clinical trial with longer duration than 96 hours of intervention of dextromethorphan supplementary to narcotics for a definitive conclusion.

Our study has multiple limitations. Most notably it is single-centered, a possible effect on external validity. Despite efforts some cofounding factors might had been overlooked. Administration of dextromethorphan through nasogastric route and not intravenously may have an impact on our study results. In conclusion, this study did not detect any adjunctive effect of dextromethorphan when added to fentanyl for control of acute pain in children admitted with acute critical care illness in PICU.

In the future, we suggest a randomized controlled trial using higher doses of dextromethorphan preferably administered intravenously. We also suggest evaluating dextromethorphan\'s role in subset of particular patients having existing chronic pain due to underlying conditions such as patients with oncologic problems who get admitted in PICU for acute critical care illness.
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###### 

Demographic characteristics. Clinical Outcomes of subjects in Groups 1 and 2 in RCT. Kolmogorov-Smirnov test used to assess distribution. nc, not computed.

  Characteristics                     Group 1: dextromethorphan (number = 16)   Group 2: placebo (number = 13)   *p* value
  ----------------------------------- ----------------------------------------- -------------------------------- -----------
  Age (Yr.)                           9.7 (8--12)                               5.54 (3.5--6)                    0.0015
  Gender: Male (number)               9                                         10                               nc
  LOS-PICU (days)                     9 (6--21)                                 12 (6--24)                       0.431
  LOS-Hospital (days)                 16.5 (9--46)                              24.5 (12--61.5)                  0.501
  PRISM                               17 (15--21)                               18.1 (15.5--22)                  0.75
  Intubated (number)                  16                                        13                               nc
  Underlying diagnosis (number)                                                                                   
   Trauma                             10                                        10                               0.57
   Hem/onco                           3                                         0                                NA
   Post-op                            2                                         1                                0.672
   Respiratory failure                1                                         1                                0.879
   Burn                               0                                         1                                NA
  Fentanyl infusion-start *µ*/kg/hr   2 (1--4)                                  2 (1--3)                         0.16
  Fentanyl infusion-end *µ*/kg/hr     3 (2--4)                                  3 (1--4)                         0.7
  Midazolam infusion-start mg/kg/hr   0.09                                      0.11                             0.36
  Midazolam infusion-end mg/kg/hr     0.16                                      0.18                             0.27

###### 

Biochemical variables of subjects in groups 1 and 2 in RCT. Groups compared via Student\'s *t*-test comparison of means. *p* \< 0.05 is significant. Values are expressed as mean and standard deviation.

                                                    Group 1: dextromethorphan (number: 16)   Group 2: placebo (number: 13)   *p  *value^*∗*^                       
  ------------------------------------------------- ---------------------------------------- ------------------------------- ----------------- --------- --------- -------
  WBC (×10^3^/mm^3^)                                Start                                    12.81                           6.337             14.92     5.937     0.673
  End                                               11.13                                    3.879                           11.31             3.225     0.894     
  Hemoglobin (g/L)                                  Start                                    103.56                          16.252            112.23    12.544    0.104
  End                                               97.81                                    12.079                          101.92            12.493    0.3747    
  Platelets (×10^3^/mm)                             Start                                    302.31                          169.591           362.54    166.289   0.348
  End                                               287.06                                   138.546                         352.00            144.741   0.228     
  Aspartate transaminase (AST) (units/L)            Start                                    44.25                           14.040            42.23     12.357    0.687
  End                                               57.80                                    32.182                          52.60             13.390    0.747     
  Alanine transaminase (ALT) (units/L)              Start                                    46.80                           11.351            42.13     12.426    0.404
  End                                               48.80                                    18.431                          45.33             21.068    0.777     
  Prothrombin time (seconds)                        Start                                    10.29                           1.816             9.77      1.964     0.419
  End                                               11.63                                    1.598                           10.90             1.969     0.433     
  International normalized ratio                    Start                                    1.00                            0.000             1.08      0.277     0.289
  End                                               1.00                                     0.000                           1.00              0.000     1         
  Activated partial thromboplastin time (seconds)   Start                                    27.29                           5.525             27.08     5.795     0.918
  End                                               26.38                                    4.104                           29.10             6.226     0.302     
  Serum sodium (mmol/L)                             Start                                    138.81                          4.969             139.77    3.632     0.591
  End                                               140.94                                   6.698                           142.38            5.268     0.545     
  Serum potassium (mmol/L)                          Start                                    3.88                            0.500             3.85      0.555     0.879
  End                                               3.94                                     0.574                           3.69              0.630     0.377     
  Serum chloride (mmol/L)                           Start                                    110.50                          7.294             106.77    6.126     0.157
  End                                               107.75                                   8.560                           106.46            4.630     0.651     
  CO~2~ (mmol/L)                                    Start                                    20.36                           4.396             19.36     7.953     0.693
  End                                               25.00                                    3.211                           25.73             3.901     0.611     
  Blood glucose (mmol/L)                            Start                                    6.67                            1.676             8.58      4.100     0.18
  End                                               6.73                                     1.870                           6.90              3.178     0.868     
  Blood urea nitrogen (mmol/L)                      Start                                    2.50                            1.211             3.54      1.391     0.048
  End                                               2.63                                     1.962                           1.69              0.751     0.12      
  Serum creatinine (*µ*mol/L)                       Start                                    32.25                           11.947            37.15     7.069     0.208
  End                                               30.00                                    14.367                          36.38             10.524    0.193     

###### 

Primary outcome in RCT. Comparison of dose(s) of fentanyl in groups. Groups compared via Student\'s *t*-test for comparison of means. *p* \< 0.05 is significant. Values are expressed as mean and standard deviation.

  ---------------------------------------------------------------------------------------------------------------------------
  Dose(s)      Group 1: dextromethorphan *µ* gram/kg/96 hrs\   Group 2: placebo *µ* gram/kg/96 hrs (number: 13)   *p* value
               (number: 16)                                                                                       
  ------------ ----------------------------------------------- -------------------------------------------------- -----------
  Cumulative                                                                                                       

   Mean        217.94                                          268                                                0.127

   Std Dev     87.7                                            81.84                                              

   SEM         21.9                                            22.7                                               

  Infusion                                                                                                         

   Mean        215.63                                          256.69                                             0.257

   Std Dev     89.27                                           101.6                                              

   SEM         22.32                                           28.2                                               

  PRN                                                                                                              

   Mean        2.31                                            3.62                                               0.101

   Std Dev     2.21                                            1.85                                               

   SEM         0.55                                            0.51                                               
  ---------------------------------------------------------------------------------------------------------------------------
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